Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target Occupancy of Scopolamine at M1 Receptor
NCT06014385Phase 1Withdrawn
- Sponsor
- Yale University
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of scopolamine (2 arms), sponsored by Yale University. Primary endpoint: Change in brain muscarinic receptor occupancy with [11C]LSN3172176 PET. Planned start Mar 2025; status: withdrawn.
02
Drugs
scopolamine
Beyond the preview
Go deeper on NCT06014385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014385.